Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
Hyonsoo Joo, Deokjae Han, Jae Ha Lee, Chin Kook Rhee
Tuberc Respir Dis. 2018;81(4):299-304.   Published online 2018 Jun 19     DOI: https://doi.org/10.4046/trd.2018.0015
Citations to this article as recorded by Crossref logo
Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases
Kartik Deshmukh, Arjun Khanna
Tuberculosis and Respiratory Diseases.2021; 84(1): 35.     CrossRef
Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes via the CREB/BDNF Signaling Pathway
Chunyuan Zhang, Zeting Xing, Meiyun Tan, Yanwen Wu, Wei Zeng
ACS Omega.2021; 6(6): 4167.     CrossRef
Updated view on the treatment of chronic obstructive pulmonary disease in Korea
Deog Kyeom Kim, Chin Kook Rhee
Journal of the Korean Medical Association.2021; 64(3): 225.     CrossRef
Spanish clinical practice consensus in internal medicine on chronic obstructive pulmonary disease patients with comorbidities (miEPOC)
Jesús Recio Iglesias, Francisco López García, Pere Almagro, José Manuel Varela Aguilar, Ramón Boixeda Viu
Current Medical Research and Opinion.2020; 36(6): 1033.     CrossRef
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Chin Kook Rhee, Deog Kyeom Kim
The Korean Journal of Internal Medicine.2020; 35(2): 276.     CrossRef
Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology
Chin Kook Rhee, Ngo Quy Chau, Faisal Yunus, Kazuto Matsunaga, Diahn‐Warng Perng
Respirology.2019; 24(10): 1018.     CrossRef
Roflumilast
Reactions Weekly.2018; 1732(1): 310.     CrossRef